Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $571.08 million. The enterprise value is $531.62 million.
| Market Cap | 571.08M |
| Enterprise Value | 531.62M |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 125.51 million shares outstanding. The number of shares has increased by 27.37% in one year.
| Current Share Class | 125.51M |
| Shares Outstanding | 125.51M |
| Shares Change (YoY) | +27.37% |
| Shares Change (QoQ) | +1.94% |
| Owned by Insiders (%) | 2.77% |
| Owned by Institutions (%) | 52.15% |
| Float | 114.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.56 |
| Forward PS | 12.25 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.19
| Current Ratio | 7.19 |
| Quick Ratio | 6.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -29.20% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -45.62% |
| Weighted Average Cost of Capital (WACC) | 13.30% |
| Revenue Per Employee | $367,939 |
| Profits Per Employee | -$532,156 |
| Employee Count | 147 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.62% in the last 52 weeks. The beta is 1.48, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -22.62% |
| 50-Day Moving Average | 4.56 |
| 200-Day Moving Average | 4.34 |
| Relative Strength Index (RSI) | 44.43 |
| Average Volume (20 Days) | 2,353,619 |
Short Selling Information
The latest short interest is 27.16 million, so 21.64% of the outstanding shares have been sold short.
| Short Interest | 27.16M |
| Short Previous Month | 25.48M |
| Short % of Shares Out | 21.64% |
| Short % of Float | 23.70% |
| Short Ratio (days to cover) | 9.05 |
Income Statement
In the last 12 months, AQST had revenue of $54.09 million and -$78.23 million in losses. Loss per share was -$0.65.
| Revenue | 54.09M |
| Gross Profit | 36.26M |
| Operating Income | -52.75M |
| Pretax Income | -78.23M |
| Net Income | -78.23M |
| EBITDA | -52.20M |
| EBIT | -52.75M |
| Loss Per Share | -$0.65 |
Balance Sheet
The company has $98.49 million in cash and $59.03 million in debt, with a net cash position of $39.46 million or $0.31 per share.
| Cash & Cash Equivalents | 98.49M |
| Total Debt | 59.03M |
| Net Cash | 39.46M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | -56.59M |
| Book Value Per Share | -0.45 |
| Working Capital | 102.02M |
Cash Flow
In the last 12 months, operating cash flow was -$45.37 million and capital expenditures -$584,000, giving a free cash flow of -$45.95 million.
| Operating Cash Flow | -45.37M |
| Capital Expenditures | -584,000 |
| Depreciation & Amortization | 544,000 |
| Net Borrowing | 9.31M |
| Free Cash Flow | -45.95M |
| FCF Per Share | -$0.37 |
Margins
Gross margin is 67.04%, with operating and profit margins of -97.52% and -144.63%.
| Gross Margin | 67.04% |
| Operating Margin | -97.52% |
| Pretax Margin | -144.63% |
| Profit Margin | -144.63% |
| EBITDA Margin | -96.51% |
| EBIT Margin | -97.52% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.37% |
| Shareholder Yield | -27.37% |
| Earnings Yield | -13.70% |
| FCF Yield | -8.05% |
Analyst Forecast
The average price target for AQST is $9.33, which is 105.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.33 |
| Price Target Difference | 105.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 33.81% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -3.25 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.25 |
| Piotroski F-Score | 4 |